Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Targeting the Roots of Cancer
- Cancer Stem Cells 2019


Cancer Stem Cells 2019

12th International Conference on Cancer Stem Cells and Oncology Research”, on July 18-19, 2019 in Valencia, Spain at the Av. de França, 11, 46023 València, Spain. The conference was marked with the attendance of Editorial Board Members of supported Allied Academies Journals, Scientists, young and brilliant researchers and talented student communities representing more than 10 countries, who made this conference fruitful and productive.

This conference was based on the Theme – “Targeting the Roots of Cancer” which included the following scientific tracks:

·          Cancer Stem Cells

·        Cancer Stem Cells & the Tumor Microenvironment

·        Circulating Tumor Cells

·        Pancreatic Cancer Stem Cells

·        Breast Cancer Stem Cells

·        Prostate Cancer Stem Cells

·        Gastric Cancer Stem Cells

·        Stem Cell Research

·        Ovarian Cancer Stem Cells

·        Lung Cancer Stem Cells

·       Cancer Stem Cells in Solid Tumours

·        Cancer Stem Cells in Brain Gliomas

·        Cancer Stem Cells and Metastasis

·        Therapies targeting Cancer Stem Cells

           Colorectal Cancer Stem Cells

·        Biomarkers of Cancer Stem Cells

·        Epigenetic Identity in Cancer Stem Cells


     We are grateful to our Speakers for their generous support and suggestions for the conference.

     Nasma Aqaqe– Tel Aviv University, Israel

     Nitin Telang– Palindrome Liaisons Consultants, USA

     Tao P Wu- Baylor College of Medicine, Houston

     Xu Chen– Ashford University-University of the Rockies, USA

     Helena Moreira– Wroclaw Medical University, Poland

     Divya Sivanesan– Indian Institute of Technology (IIT)-Madras, India 

    A scientific session on Day 1 was chaired by Adam Frosh, Lister Hospital, United Kingdom

    Allied Academies has taken the grand privilege of felicitating Cancer Stem Cells 2019 Organizing Committee, Editorial Board Members and Keynote Speakers who supported the success of this event.

    The esteemed guests, Keynote speakers, well-known researchers and delegates shared their innovative research and vast experience through their presentations at the podium of Cancer Stem Cells 2019. We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance.


    Cancer Stem Cells 2019 is anamalgamation of several esteemed academic and scientific associations known forpromoting scientific temperament. 
    We invite all the participants from all over the world to attend"12th International Conference on Cancer Stem Cells and Oncology Research”, on July 18-19, 2019 in Valencia, Spain which includes promptkeynote presentations, oral talks, poster presentations and exhibitions.
    Cancer stem cells (CSCs) are cancercells (found within tumors or haematological cancers) that possesscharacteristics associated with normal stem cells, specifically the ability togive rise to all cell types found in a particular cancer sample. CSCs aretherefore tumorigenic (tumour-forming), perhaps in contrast to othernon-tumorigenic cancer cells. CSCs may generate tumors through the stem cell processesof self-renewal and differentiation into multiple cell types. Such cells arehypothesized to persist in tumors as a distinct population and cause relapseand metastasis by giving rise to new tumors. Therefore, development of specifictherapies targeted at CSCs holds hope for improvement of survival and qualityof life of cancer patients, especially for patients with metastatic disease.

    Cancer Stem Cells 2019 is a platform to fulfill the prevailing gaps in thetransformation of this science of hope, to serve promptly with solutions to allin the need. Cancer Stem Cells 2018 will have an anticipated participation of120+ delegates across the world to discuss the conference goal.

    About Organizers:
    It is one of the leading Open Access publishers and organizers of international scientific conferences and events every year across USA, Europe & Asia. It has so far organized 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on Medical, Pharma, Engineering, Science, Technology and Businesswith 700+ peer-reviewed open access journals inbasic science, health, and technology.

    Scientific Sessions:
    Cancer Stem Cells 2019 will encompass recent researches and findings in Cancer stem cells technologies, Cancer stem cells therapies and transplantation,current understanding  of cell plasticity in cancer and other advancementsin Cancer stem cells research and cell science. Cancer Stem Cells 2019 will be a great platform for research scientists and young researchers to sharetheir current findings in this field of applied science. The major scientificsessions in Cancer Stem Cells 2019 will focus on the latest and excitinginnovations in prominent areas of Cancer cell science and Cancer stem cellsresearch.

    Target Audience:
    Eminentpersonalities, Directors, CEO, President, Vice-president, Organizations,Associations Heads and Professors, Research scientists, Cancer Stem Celllaboratory heads, Post-docs, Students other affiliates related to the area ofCancer Stem cells research, regenerative medicine can be as Target Audience.

    Welcome Message

    We welcome all the attendees, speakers, sponsor’s and other research expertise from all over the world to the "12th International Conference on Cancer Stem Cells and Oncology Research” (Cancer Stem Cells-2019) which is going to be held during July 18-19 2019 in Valencia, Spain. We are very much honored to invite you all to exchange and share your views and experience on Caner Stem Cells: Targeting Cancer Stem Cells to Transform Cancer Therapies.

    Cancer Stem Cells 2019 is anamalgamation of several esteemed academic and scientific associations known forpromoting scientific temperament. 
    We invite all the participants from all over the world to attend"12th International Conference on Cancer Stem Cells and Oncology Research”, on July 18-19, 2019 in Valencia, Spain which includes promptkeynote presentations, oral talks, poster presentations and exhibitions.

    Sessions and Tracks

    We invite allthe participants from all over the world to attend "12th InternationalConference on Cancer Stem Cells and Oncology Research" during July 18-19 2019  Valencia, Spain which includes prompt keynote presentations, oraltalks, poster presentations and Exhibitions.

    Cancer Stem Cells
    Cancer stem cells are rare immortal cells within a tumourthat can both self-renew by dividing and give rise to many cell types thatconstitute the tumour, and can therefore form tumours. Such cells have beenfound in various types of human tumours and might be attractive targets forcancer treatment.

    Cancer Stem Cells and Metastasis
    Metastasis isthe spread of a cancer or other disease from one organ or part of the body toanother without being directly connected with it. When cancer cells break awayfrom a tumour, they can travel to other areas of the body through thebloodstream or the lymph system. The lungs, liver, brain, and bones are themost common metastasis locations from solid tumors.
    CancerStem Cells and the Tumor Microenvironment
    A growingbody of evidence indicates that the tumor microenvironment contributes to tumorgrowth and viability, while significant advances are being made in theunderstanding of cancer stem cells and tumor initiating cells. The session willdiscuss on breaking developments on novel tumor-killing strategies andpreclinical and clinical projects which are exploiting cancer stem cells, theinflammatory component of tumors, and the tumor microenvironment fortherapeutic intervention.

    Bio-markersof Cancer Stem Cells
    Bio-marker is a biological molecule found in blood, otherbody fluids, or tissues that is a sign of a normal or abnormal process, or of acondition or disease. A biomarker may be used to see how well the body respondsto a treatment for a disease or condition.
    CancerGenomics & Metabolomics
    The mainconcept and idea of oncogenomics are to check a new groupof oncogenes or tumour suppressor genes that may give new areas of researchinto cancer diagnosis, predicting clinical outcome of cancers and new targetsfor cancer therapies.  Oncogenomics is a sub-field of genomics thatcharacterizes cancer-associated or cancer-related genes. It focuses mainly ongenomic, epigenomic and transcript alterations in cancer. The Gleevec,Herceptin and Avastin are the targeted cancertherapies which gave a new way for oncogenomics to elucidate new targets forcancer treatment. The metabolome represents the collection of all metabolitesin a biological cell, tissue, organ or organism that are the end products ofcellular processes and gives physiology of the given cell. One of thechallenging aspects of systems biology and functional genomics is to integrateproteomic, transcriptomic, and metabolomic information which provide a betterunderstanding of cellular biology.
    Immune systems in stem cells and cancer
    Immuno-oncology is the new and emerging field of cancerresearch that works to understand the interaction of the immune system withcancers cells and finds ways for the harness of the patient’s immune system totreat or prevent cancer. It targets only the immune system, not the cancercells. Recent advances in our understanding of antigen recognition,presentation and the molecules involved in T and Bcell activation have provided new and excited immunotherapeuticstrategies which can be used against the cancer cells. Some success in animalmodels has been observed and some molecules are now being in clinical trials.
    Clinicalresearch and trials in stem cells and cancer
    Cancerresearch focuses on stem cells present in malignant tumors. Researchers believe current cancertreatments sometimes fail because they don't destroy the cancer stem cells.Think of cancer as a weed: the stemcells are the root while the remaining majority of the cellsare the part of the weed above ground. If you remove only the leaves but notthe root, the weed will grow back. The same is true for cancer: if you do notkill the cancer stem cells, the cancer is likely to return.
    Stem Cell Transplantation for Cancer
    Stem cell transplant (also called peripheral blood stemcell transplant) is a treatment to try to cure some types of cancer, such as leukemia, lymphoma and myeloma.You have very high doses of chemotherapy, sometimes with whole body radiotherapy.This has a good chance of killing the cancer cells but also kills the stemcells in the bone marrow. Stem cell transplant means that you can havehigher doses of treatment. So there may be more chance of curing thecancer than with standard chemotherapy.

    CancerStem Cells Epigenetics
    Epigeneticalterations including DNA methylation and histone modifications are the keyfactors in the differentiation of stem cells into different tissue subtypes.The generation of cancer stem cells (CSCs) in the process of carcinogenesis mayalso involve similar kind of epigenetic reprogramming where, in contrast, itleads to the loss of expression of genes  specific to the differentiatedstate and regaining of stem cell-specific characteristics. The most importantpredicament with treatment of cancers includes the non-responsive quiescentCSC.Characterizing the epigenetic marks of CSCs and the associated signallingcascades might help in developing therapeutic strategies againstchemo-resistant cancers.
    Breast Cancer Stem Cells
    Breast cancer stem cells - the first to be identified ina solid tumour - were discovered in 2003 by scientists at the U-M ComprehensiveCancer Center. U-M scientists found that just a few cancer stem cells areresponsible for the growth and spread of breast cancer. Unless the cancer stemcells are destroyed, the tumour is likely to come back and spread malignantcells to other parts of the body, a process called metastasis
    Pancreatic Cancer Stem Cells
    Pancreatic cancer stem cells have some similarities tocancer stem cells found in other types of cancer; however, there also appear tobe some significant differences. This is why it is important to study thefunction of these cells in the specific cancer in which these cells arise tobest understand their function. Regardless of the organ in which they arefound, cancer stem cells appear to be responsible for the propagationof cancer and for its spread to other organs in the body. 
    Embryonic Stem Cells
    Embryonic stem cells (ES cells) are pluripotent stemcells derived from the inner cell mass of a blastocyst, an early-stagepreimplantation embryo. Human embryos reach the blastocyst stage 4–5 days postfertilization, at which time they consist of 50–150 cells. Isolating the embryoblast or inner cell mass (ICM) results in destruction of the blastocyst,which raises ethical issues, including whether or not embryos at thepre-implantation stage should be considered to have the same moral or legalstatus as more developed human beings.
    Cancer Stem Cells in Brain Gliomas
    Glioblastoma (GBM) is the most prevalent and malignantprimary brain tumor and contains self-renewing, tumorigeniccancer stem cells (CSCs) that contribute to tumor initiationand therapeutic resistance. As normal stem and progenitor cells participate intissue development and repair, these developmental programs re-emerge in CSCsto support the development and progressive growth of tumors.
    Hematopoietic and Chord blood stem cells
    Cord blood stem cells are derived from the blood found inthe vein of the umbilical cord. Cord blood contains immunologicallynaïve, hematopoietic stem cells known as HSCs which have beenused in medical treatments for 25 years. They are capable of generating themultitude of cell types found in the bloodstream, including red blood cells orerythrocytes; different types of white blood cells, such as lymphocytes andneutrophils; and megakaryocytes which ultimately form platelets.
    LungCancer Stem Cells
    Lung cancer remains a major cause of cancer-relatedlethality because of high incidence and recurrence in spite of significantadvances in staging and therapies. Recent data indicates that stem cellssituated throughout the airways may initiate cancer formation. These putativestem cells maintain protumorigenic characteristics including high proliferativecapacity, multipotent differentiation, drug resistance and long lifespanrelative to other cells. Stem cellsignalling and differentiation pathways are maintained withindistinct cancer types, and destabilization of this machinery may participate inmaintenance of cancer stem cells. Characterization of lungcancer stem cells is an area of active research and is criticalfor developing novel therapies. This review summarizes the current knowledge onstem cell signalling pathways and cell markers used to identify the lung cancerstem cells.
    Prostate Cancer Stem Cells
    Prostate Cancer is now a common disease in men over 50years of age. Medical therapies for prostate cancer are based on discoveriesfrom the mid-twentieth century, and in the long term are rarely curative. Mosttreatments are directed towards an androgen receptor-expressing, highlyproliferative target cell, which does indeed form the vast majority of cells ina prostate tumour. However, by invoking the existence of a cancer stem cell which,like normal epithelial stem cells in the prostate, does not expressandrogen receptor and is relatively quiescent, the observed resistance to mostmedical therapies can be explained. The phenotype ofthe prostatecancer stem cells is that of a basal cell and cultures derivedfrom cancers, but not benign tissues, express a range of prostatecancer-associated RNAs.
    Cancer Stem Cells in Solid Tumors
    Cancer stemcells (CSCs) are cells that drive tumorigenesis, as well as giving rise to alarge population of differentiated progeny that make up the bulk of the tumour,but that lack tumorigenic potential.
    Gynaecology oncology
    Cervical Cancer is one of the mostcommon cancers in women worldwide. But in the United States and other countrieswhere cervical cancer screening is routine, this cancer is not so common. Mostcervical cancer is caused by a virus called Human papillomavirus or alsospelled as HPV. There are many types of the HPV virus, but all of HPV does not causecervical cancer. Some of them cause genital warts, but other types may not showany Cervical Cancer symptoms and signs. An infection may go away on its own.But sometimes it can cause genital warts or can also lead to cervical cancer,it's important for women to have regular Pap tests. A Pap test can find changesin cervical cells before they turn into cancer cells. Thus treatment of these cell changes, preventcervical cancer.
    Pediatric Oncology
    PediaticOncology is a branch of medicine which deals with the medicalcare of infants, children, and adolescents. The word pediatrics and itscognates mean "healer of children"; they derive from two Greek words:pais "child" and iatros "doctor, healer". The age limit,from birth up to 18-21 yrs. Pediatricians work both in primary care physiciansand hospitals, especially they works in a specialized subfields such asneonatology. Paediatric oncologists diagnose, treat, and managechildren, suffering from cancers which include leukaemia, lymphomas, brain tumours, bone tumours, and solidtumors. A medical practitioner who specializes in this area is called as apaediatrician. The body of an infant or neonate is substantiallyphysiologically different when compare to an adult. Congenital defects, geneticvariance and developmental issues are some greater concern to paediatricians ascompare to adult physicians.
    Neuro Oncology
    Neurooncology is the study of brain and spinal cord neoplasms, whichare very dangerous and leads to risking of life. Some of them are astrocytoma atype of brain cancer; glioma is type of tumor starts at brain or spine, glioblastoma which is also called as glioblastomamultiforme (GBM), ependymoma, pontine glioma, and brain stem tumors. Brain tumors can occur at any age of an individual, fromprimary stage to late in life. Most of the primary tumours are found common inwomen. A person who is trained in the diagnosis and treatment of nervous systemis known as Neuro oncologist. Primary malignant brain tumours are found 5,000people in UK each year and others are found with secondary tumours.
    Carcinogenesis and Mutagenesis
    Carcinogenesis alsocalled as oncogenesis or tumorigenesis, leads to formation of a cancer, wherenormal cells are turned into cancerous. Thus the process is characterized bychanges at epigenetic, genetic and cellular levels. Themain idea of carcinogenesis is to check new group ofoncogenes or tumour suppressor genes that may give new areas of research intocancer diagnosis, predicting clinical outcome of cancers and new targetsfor cancertherapies. There are also many epigenetic changes that alter whethergenes are expressed or not expressed. The presence of an abnormal number ofchromosomes in a gene is known as Aneuploidy. It is a genomic change, not amutation. Large-scale mutations involve the deletion or gain of a portion of achromosome. Genomic amplification occurs only when cell gains 20 or more than20 copies of a small chromosomal region, containing one or more oncogenes andapart to it adjacent genetic material. Mutagenesis isa process by which, genetic information of an species or an organism is changedand thus results in a mutation and can lead to cancer and various heritablediseases, done by physical, chemical or biological agents. In the laboratories,Mutagenesis plays an important technique where, DNA mutations are intentionallyengineered so that they can produce mutant strains, proteins, or Gene of anorganism.
    Radiation Oncology
    The use ofradiation to treat cancer is defined as RadiationOncology. X-rays, gamma rays, or electrons are some of the radiationsused to treat the Radiation Oncology. A physician who uses ionizing radiation(such as megavoltage X-rays or radionuclides) in the treatment of cancer isknown as Radiation Oncologist. Thus Oncologists uses radiation to treatsome of the benign diseases and benign tumours. Radiation oncology is one ofthe primary specialties among surgical and medicaloncology, which are involved in the treatment of cancer. The fieldof radiation oncology gives the integration of radiation therapy intomultimodal treatment approaches. Radiation Oncology focuses on all aspects ofresearch, which impacts on the treatment of cancer using radiation. It not onlyshows findings in molecular and cellular radiation biology but also in widerange of radiation physics, radiation technology, and clinicaloncology.
    Hemato-oncology and BloodCancers
    Hematologiconcology isthe branch of medicine which deals with the study, diagnosis, treatment, andprevention of many diseases related to blood. Haematology involves the study ofetiology. It involves the treatment of diseases which usually affect theproduction of blood and its components; it includes blood cells (RBC, WBC,etc…), haemoglobin, blood proteins, bone marrow, spleen, and also mechanism ofcoagulation. These kinds of diseases include hemophilia, blood clots, otherbleeding disorders and mostly blood cancers such as leukaemia, myeloma, and lymphoma.  Blood cancers affect the production ofmost of the blood cells in the body. These types of cancers start in patient’sbone marrow where the blood is produced. Stem cells mature and develop intothree types of blood cells, which are White blood cells, red blood cells orplatelets; they are smallest type of blood cell present in the bone marrow. Thenormal growth of blood cell is stopped by the uncontrolled growth of abnormalblood cells, which are generally cancerous.
    Melanoma and other skin Cancer
    Melanoma is one typeof skin Cancer that arises when the melanocytes become cancerous. It is most common type ofskin cancer but very serious if avoided. Melanoma, also called malignantmelanoma, develops from the pigment-containing cells known as melanocytes. Ittypically occurs in the skin and rarely in the mouth, intestines, or eye.Individuals with low levels of skin pigment when expose to ultra violet lightcauses Melanoma. The use of sunscreen and avoiding UV light may preventmelanoma disease to a larger extent. Further treatment removal by surgery. Skincancers are majorly arises from the skin. They are mainly due to abnormalgrowth of the cells that have the ability to spread to all other parts of thebody of an individual. Basal-cell skin cancer (BCC), squamous-cellskin cancer (SCC)and melanoma are the common types of skin cancer seen in most of theindividuals. Among these three BCC and SCC are commonly known as non-melanomaskin cancer (NMSC). Thus the non-melanoma skin cancer can be easily cured.

    Market Analysis Report

    USA: According to a report published by W.H.O cancer fatalities are expected to increase from 14 million in 2012 to 22 million in 2020, 8.2 million deaths worldwide were due to cancer, colorectal cancer constituted 8.4%, breast cancer constituted 6.0% and liver constituted 9.0% in 2012.

    Europe: Global Cancer stem cell market is expected to grow at a CAGR of 23% for the forecasted period of 2015-2020. Cancer Stem cell research is also being used to study genetic disorders, birth defects and other growth factors.

    Middle East: Cancer Stem Cell Therapy was conditionally approved in Canada in 2012. Mesenchymal Stem Cells are purified from the marrow, cultured and packaged, with up to 10,000 doses derived from a single donor. The doses are stored frozen until needed.

    Asia Pacific: According to a new market research report, ‘Global Cancer Stem Cell Market – Growth, Trends & Forecasts (2015-2020)’, published by Mordor Intelligence, the Global market is expected to be worth US$ 30.25 billion by the end of 2020, The Global market for Stem Cells is expected to grow at a CAGR of 13.7% during the period of (2015-2020).

    Organizing Committee
    OCM Member
    Jinsong Liu
    Professor, M. D. Anderson Cancer Center
    The University of Texas
    Houston, USA
    OCM Member
    Thierry Virolle
    Institut de Biologie Valrose- Ibv
    Nice, France
    OCM Member
    Xianming Mo
    West China Hospital of Sichuan University
    Gungzhou, China
    OCM Member
    Ilio Vitale
    The University of Rome Tor Vergata
    Rome, Italy
    OCM Member
    Jiangwen Zhang
    Associate Professor, School of Biological Sciences
    The University of Hong Kong, Hong Kong
    Tai Po, Hong Kong
    OCM Member
    Joo-Hyeon Lee
    Department of Zoology, University of cambridge
    Exeter, United Kingdom
    OCM Member
    Claire Acquaviva
    Marseille Cancer Research Centre
    Marseille, France
    OCM Member
    Emmanuelle Charafe-Jauffret
    Institut Paoli-Calmettes
    Marseille, France
    OCM Member
    Dean G Tang
    Roswell Park Cancer Institute
    Newyork, USA
    OCM Member
    Jingfang Ju
    Stony Brook University
    New York, USA
    OCM Member
    Yong Li,
    University of New South Wales
    Kensington, Australia
    OCM Member
    Philippe Juin
    Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA)
    Nantes, France

    Av. de França, 11, 46023 València, Spain


    Join The Discussion

    Contact Desk


    John Smith

    +44 800 086 8979

    Whats App Queries

    John Smith

    +44 1562 548899

    Special Issues
    All accepted abstracts will be published in respective Allied Academies Journals.
    Abstracts will be provided with Digital Object Identifier by

    Allied Academies Global Conference Directory

    Mail us at

    Program enquiry
    Whats App Queries
    More details about

    Terms and Conditions

    Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.

    Registration fees do not include insurance of any kind.

    Please note that any (or) all transportation and parking is the responsibility of the registrant.

    Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization. This conference is not associated with any commercial meeting company.

    Requesting an Invitation Letter
    For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact to request a personalized letter of invitation.
    Regarding refunds, all bank charges will be for the registrant's account.
    All cancellations or modifications of registration must be made in writing to

    Cancellation Policy
    If Allied Academies cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of cancellation.

    If Allied Academies postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of postponement.

    Transfer of registration
    All fully paid registrations are transferable to other persons from the same organization if registered person is unable to attend the event. Transfers must be made by the registered person in writing to . Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.
    Registration can be transferred to one conference to another conference of Allied Academies if the person is unable to attend one of the conferences.
    However, Registration cannot be transferred if it is intimated within 14 days of the respective conference.
    The transferred registrations will not be eligible for Refund.

    Visa Information
    Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.
    Allied Academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.
    Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies, including the inability to obtain a visa.

    Refund Policy:
    If the registrant is unable to attend and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:
    Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-
    • Before 60 days of the conference: Eligible for Full Refund less $100 service Fee
    • Within 60-30 days of Conference: Eligible for 50% of payment Refund
    • Within 30 days of Conference: Not eligible for Refund
    • E-Poster Payments will not be refunded.

    Accommodation Cancellation Policy:
    Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

    Highlights from last year's Convention

    Authorization Policy

    Copyright © 2019-2020 Allied Academies, All Rights Reserved.